Do you want to read an article? Please log in or register.
Ten-Year outcomes of transcatheter versus surgical aortic valve replacement: extended follow-up from the OBSERVANT study
Further Publications
Related content
Lung Cancer
Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data
Lung Cancer
Zhang M, Deng C, Fu F, Li Y, Zhang Y, Chen H
doi: 10.1016/j.lungcan.2025.108451
Pulmonary Fibrosis
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
J Cyst Fibros
Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB
doi: 10.1016/j.jcf.2025.04.012
RECOMMENDED
Pulmonary Fibrosis
Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Højte C, Olsen MF, Faurholt-Jepsen D, Jørgensen MH, Pressler T, Leo-Hansen C, Bryrup T, Jeppesen M, Olesen HV, Petersen J, Katzenstein TL, Nielsen BU, Skov M, TransformCF Study Group
doi: 10.1016/j.jcf.2025.08.008
COPD
TETRIS - Prospective study to observe clinical outcomes of triple therapy in COPD patients: up to 12 months interim analysis
Respir Med
Rohde G, Vogelmeier CF, Beeh KM, Kardos P, Paulsson T, Watz H, Westermayer B, Mohan T, Noorduyn SG, Claussen J
doi: 10.1016/j.rmed.2025.108597
Further Publications
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies
Lancet Respir Med
Burgel PR, Da Silva J, Girodon E, Durieu I, Reynaud-Gaubert M, Murris-Espin M, Chiron R, Grenet D, Ramel S, Mely L, Hamidfar R, Douvry B, Houdouin V, Audousset C, Macey J, Mittaine M, Weiss L, Cosson L, Danner-Boucher I, Reix P, Baravalle M, Burnet E, Sermet-Gaudelus I, Martin C, Paillasseur JL, French Cystic Fibrosis Reference Network study group
doi: 10.1016/S2213-2600(25)00190-0
Further Publications
Effect of Nirsevimab as a Primary Preventive Strategy on the Incidence, Severity, and Viral Etiology of Bronchiolitis: A Four-Year Observational Study
Pediatr Pulmonol
Presti S, Parisi GF, Tosto M, Nizzari A, Campo E, Pecora G, Papale M, Manti S, Leonardi S
doi: 10.1002/ppul.71451
Pulmonary Fibrosis
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study
J Clin Med
Lucca F, Meneghelli I, Tridello G, Buniotto F, Cucchetto G, Volpi S, Pintani E, Bezzerri V, Cipolli M
doi: 10.3390/jcm14124335
RECOMMENDED
Interstitial Lung DiseasePneumonia
Clinical Profiles, Survival, and Lung Function Outcomes in ANCA-Associated Interstitial Lung Disease: An Observational Study
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Valero-Martínez C, Valenzuela C, Baldivieso Achá JP, Martínez-Besteiro E, Quiroga-Colina P, Alfranca A, Vicente-Rabaneda EF, Muñiz SH, Castañeda S, García-Vicuña R
doi: 10.3390/jcm14010229
Further Publications
Cutoff points for sedentary behavior and their capacity to predict mortality in individuals with COPD: A 12- year follow-up study
Chron Respir Dis
Santin L, Silva H, Tofoli TM, Medeiros L, Furlanetto KC, Pitta F
doi: 10.1177/14799731251366956